High Yield Overview

Contrast Agents and Safety

Iodinated and Gadolinium Contrast in Orthopaedic Practice

0.04%Severe reaction rate (iodinated)

5-10%Mild reaction rate (iodinated)

eGFR 30Threshold for CIN risk (iodinated)

NSFNephrogenic systemic fibrosis (gadolinium)

AdrenalineFirst-line anaphylaxis treatment

IV salineCIN prevention hydration

Low-osmolarPreferred iodinated contrast type

MacrocyclicSafest gadolinium chelate type

Contrast Reaction Classification

Mild: Urticaria (limited), nausea, warmth, metallic taste, mild pruritus, sneezing

Moderate: Diffuse urticaria, facial oedema, bronchospasm (mild), tachycardia, hypotension (transient)

Severe: Anaphylaxis, severe bronchospasm, laryngeal oedema, cardiovascular collapse, seizures, loss of consciousness

Key: Mild reactions are self-limiting. Moderate reactions require treatment and monitoring. Severe reactions are life-threatening emergencies requiring immediate adrenaline.

Critical Must-Knows

Iodinated contrast (CT): reactions are anaphylactoid (NOT IgE-mediated), cannot be predicted by skin testing, and require immediate treatment if severe.
Gadolinium contrast (MRI): associated with nephrogenic systemic fibrosis (NSF) in patients with severe renal impairment (eGFR less than 30).
Contrast-induced nephropathy (CIN) is a transient decline in renal function after iodinated contrast — risk is highest with pre-existing renal impairment.
Adrenaline (epinephrine) 0.5mg IM is the FIRST-LINE treatment for anaphylaxis from contrast media — not antihistamines or steroids.
Premedication with steroids and antihistamines does NOT prevent all reactions but reduces their severity.

Examiner's Pearls

"
Iodinated contrast reactions are NOT true allergies — they are anaphylactoid (direct mast cell degranulation, not IgE-mediated).
"
A previous iodinated contrast reaction increases the risk of future reaction 5-6 fold but does NOT predict the severity of the next reaction.
"
Metformin should be withheld for 48 hours after iodinated contrast in patients with eGFR less than 30 due to the risk of lactic acidosis if AKI develops.
"
Gadolinium-based contrast agents are classified as Group I (macrocyclic, safest), Group II (macrocyclic, safe), and Group III (linear, highest NSF risk).
"
Breastfeeding does NOT need to be interrupted after iodinated or gadolinium contrast — less than 0.04% of dose enters breast milk.

Exam Warning

Contrast agent safety is a high-yield exam topic, particularly the management of anaphylaxis and renal protection strategies. You must be able to: classify contrast reactions, manage anaphylaxis (adrenaline first-line, dose, route), explain the mechanism of contrast-induced nephropathy, discuss prevention strategies (hydration, eGFR thresholds), and differentiate iodinated from gadolinium contrast risks. A common trap is treating anaphylaxis with antihistamines instead of adrenaline.

Mnemonic

ABCDAContrast Reaction Management

Adrenaline IM (0.5mg = 0.5mL of 1:1000)

FIRST-LINE for anaphylaxis. Give immediately IM into anterolateral thigh. Repeat every 5 minutes if no improvement

Breathing support (oxygen, bronchodilators)

High-flow oxygen via mask. Salbutamol nebuliser for bronchospasm. Consider intubation if airway compromise

Circulation (IV fluids, positioning)

Large-bore IV access. Rapid IV saline bolus (500mL-1L). Supine with legs elevated (Trendelenburg) for hypotension

Drugs (antihistamines, hydrocortisone — SECOND LINE)

Promethazine 25mg IV or chlorpheniramine 10mg IV. Hydrocortisone 200mg IV. These are ADJUNCTS, not first-line

Arrest team and monitoring

Call for help early. Continuous monitoring: ECG, SpO2, blood pressure. Minimum 6-hour observation after severe reaction

Memory Hook:ABCDA: Adrenaline first, then Breathing, Circulation, Drugs, and Arrest team. Remember: ADRENALINE saves lives, not antihistamines.

Mnemonic

HYDRATECIN Prevention

Hydration (IV saline — most important)

IV 0.9% normal saline: 1mL/kg/hr for 12 hours before and 12 hours after contrast administration

Yield (use lowest volume of contrast)

Minimise the contrast volume used — use the lowest dose that provides adequate diagnostic images

Don't use high-osmolar contrast

Low-osmolar or iso-osmolar non-ionic contrast produces less nephrotoxicity than high-osmolar ionic agents

Renal function check (eGFR)

Check eGFR before contrast administration. CIN risk rises significantly when eGFR drops below 30

Avoid nephrotoxic drugs

Withhold NSAIDs, aminoglycosides, and other nephrotoxins. Withhold metformin if eGFR is below 30

Time the repeat contrast studies

Allow at least 48-72 hours between contrast studies to allow renal recovery

Evaluate creatinine 48-72 hours post-contrast

Check renal function 48-72 hours after contrast to detect CIN (defined as 25% or 44 micromol/L rise in creatinine)

Memory Hook:HYDRATE to protect the kidneys: Hydration is the single most effective CIN prevention strategy.

Mnemonic

NSFGadolinium Safety

Nephrogenic Systemic Fibrosis

A potentially fatal fibrosing condition affecting skin, joints, and internal organs — caused by gadolinium in severe renal impairment

Severe renal impairment (eGFR less than 30)

NSF risk is almost exclusively in patients with eGFR less than 30. Group I (macrocyclic) agents have the lowest risk

Free gadolinium is toxic

NSF is caused by free (unchelated) gadolinium released from contrast agents. Linear agents release more free gadolinium than macrocyclic agents

Memory Hook:NSF: the unique and potentially fatal risk of gadolinium contrast in patients with severe kidney disease.

Overview

Contrast agents are used in orthopaedic imaging to enhance tissue differentiation and improve diagnostic accuracy. Iodinated contrast is used for CT, fluoroscopy, and conventional arthrography, while gadolinium-based contrast agents (GBCAs) are used for MRI. Although contrast-enhanced imaging is not routinely required for most musculoskeletal conditions, it plays a critical role in specific scenarios: tumour staging, infection assessment, vascular evaluation, arthrography, and post-operative assessment.

Understanding contrast agent pharmacology, reaction management, and renal safety is essential for all orthopaedic surgeons, not just radiologists, because orthopaedic patients frequently require contrast-enhanced imaging and the operating surgeon may need to manage contrast reactions in the perioperative setting.

Iodinated Contrast (CT/Fluoroscopy)

Iodinated contrast works by absorbing X-rays due to the high atomic number of iodine (Z=53). Modern agents are non-ionic and low-osmolar (e.g., iohexol, iopamidol), which significantly reduced reaction rates compared to older ionic high-osmolar agents. Iodinated contrast is excreted renally and is the agent associated with contrast-induced nephropathy (CIN). Orthopaedic applications include: CT angiography, contrast-enhanced tumour assessment, and CT arthrography.

Gadolinium Contrast (MRI)

Gadolinium is a paramagnetic metal that shortens the T1 relaxation time of nearby water molecules, causing T1-bright signal at the site of accumulation. GBCAs are chelated (bound to a molecular cage) to reduce toxicity. The key safety concern is nephrogenic systemic fibrosis (NSF) in severe renal impairment (eGFR less than 30). Modern macrocyclic agents (e.g., gadobutrol, gadoterate) have the lowest NSF risk due to their more stable chelate structure. Orthopaedic applications: MR arthrography, tumour enhancement, infection assessment, post-operative evaluation.

Clinical Imaging

Imaging Gallery

Contrast-enhanced imaging demonstrating the effect of iodinated or gadolinium contrast on tissue differentiation — Contrast-enhanced imaging demonstrating how contrast agents improve tissue differentiation. Enhanced images show increased signal/density in vascularised tissues, allowing better delineation of tumour margins, inflammatory processes, and vascular structures compared to non-enhanced imaging.Credit: Open-i (NIH) (Open Access (CC BY))

Imaging demonstrating contrast enhancement patterns in musculoskeletal pathology — Contrast enhancement patterns in musculoskeletal pathology. Different pathological processes show characteristic enhancement patterns: rim enhancement in abscess, heterogeneous enhancement in tumours, and diffuse enhancement in synovitis. These patterns aid in differential diagnosis.Credit: Open-i (NIH) (Open Access (CC BY))

Systematic Approach

Pre-Contrast Safety Assessment

Pre-Contrast Safety Checklist

Step	Assessment	Action Required
1. Previous contrast reaction	Ask about any prior reaction to contrast media and its severity	If prior reaction: risk is 5-6x higher. Consider premedication, alternative imaging, or radiology consultation
2. Renal function	Check eGFR within the last 3 months for iodinated contrast; within 6 months for gadolinium	eGFR less than 30: high CIN risk (iodinated) and NSF risk (gadolinium). Hydrate and use minimum contrast volume
3. Allergies and asthma	History of asthma, atopy, or other drug allergies	Asthma increases contrast reaction risk 5-10x. Ensure bronchodilator available. Consider premedication
4. Medications	Metformin, NSAIDs, aminoglycosides, diuretics	Withhold metformin 48h post-contrast if eGFR less than 30. Avoid nephrotoxins. Ensure adequate hydration
5. Pregnancy and breastfeeding	Pregnancy status and breastfeeding	Iodinated contrast: avoid in pregnancy unless essential. Gadolinium: avoid in pregnancy (crosses placenta). Breastfeeding: can continue after both agents
6. Emergency equipment	Resuscitation equipment must be immediately available	Adrenaline, oxygen, IV access, suction, monitoring equipment must be on-site whenever contrast is administered

Iodinated Contrast Reactions

Classification and Management of Iodinated Contrast Reactions

Contrast Reaction Classification and Management

Severity	Symptoms	Incidence	Management
Mild	Limited urticaria, pruritus, nausea, warmth, metallic taste, sneezing, mild headache	5-10%	Observation only. Most resolve spontaneously. May give oral antihistamine if symptoms are bothersome
Moderate	Diffuse urticaria, facial/laryngeal oedema (mild), bronchospasm (responsive), hypotension (transient, responds to fluids)	1-3%	Medical treatment required: adrenaline 0.3-0.5mg IM if progressing, IV fluids, salbutamol nebuliser for bronchospasm, antihistamine IV, observation minimum 4 hours
Severe (Anaphylaxis)	Cardiovascular collapse, severe bronchospasm, laryngeal oedema with stridor, loss of consciousness, seizures, respiratory arrest	0.04%	ADRENALINE 0.5mg IM IMMEDIATELY (1:1000, anterolateral thigh). Repeat every 5 min. High-flow oxygen. Large-bore IV saline. Call arrest team. Transfer to resuscitation area

Key principles:

Iodinated contrast reactions are anaphylactoid (direct mast cell degranulation), NOT true IgE-mediated allergies. This means they can occur on first exposure and cannot be predicted by skin testing.
Adrenaline is ALWAYS the first-line treatment for anaphylaxis — it reverses bronchospasm, supports blood pressure, and reduces oedema.
Antihistamines and corticosteroids are SECOND-LINE adjuncts — they should NEVER delay adrenaline administration.
All moderate and severe reactions require a minimum observation period and documentation for future reference.

Contrast-Induced Nephropathy

Contrast-Induced Nephropathy (CIN)

CIN is defined as an acute decline in renal function (rise in serum creatinine of 25% or more, or 44 micromol/L or more above baseline) occurring within 48-72 hours of iodinated contrast administration, in the absence of another cause.

CIN Risk Factors and Prevention

Category	Risk Factor	Management
Pre-existing renal disease	eGFR less than 30 (highest risk), eGFR 30-60 (moderate risk)	IV hydration: N/S 1mL/kg/hr for 12h pre and 12h post. Use lowest contrast volume
Diabetes mellitus	Diabetic nephropathy compounds the risk, especially with metformin	Withhold metformin for 48h post-contrast if eGFR less than 30 (risk of lactic acidosis if AKI develops). Check creatinine before restarting
Dehydration	Hypovolaemia reduces renal perfusion and concentrates contrast in tubules	Ensure adequate hydration; correct volume depletion before contrast
Nephrotoxic drugs	NSAIDs, aminoglycosides, ACE inhibitors, diuretics	Withhold nephrotoxins if clinically safe. Ensure volume status is optimised
High contrast volume	Larger volumes increase the osmotic and direct toxic load on the kidneys	Use the minimum effective dose. Avoid repeated contrast studies within 48-72 hours
Contrast type	High-osmolar ionic contrast has the highest CIN risk	Use low-osmolar or iso-osmolar non-ionic contrast for all patients

CIN Natural History

CIN is typically transient: creatinine peaks at 3-5 days and returns to baseline within 7-14 days in the majority of cases. However, a small proportion of patients (particularly those with severely impaired baseline renal function) may develop persistent renal impairment or require temporary dialysis. The risk of permanent dialysis-dependent renal failure from CIN is very low in the general population but clinically significant in high-risk patients (eGFR less than 15, diabetic nephropathy, heart failure).

Evidence Base

Incidence and Management of Contrast Reactions

Registry Study

Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K • Radiology (1990)

Key Findings:

The overall adverse reaction rate was 12.66% for ionic high-osmolar contrast vs 3.13% for non-ionic low-osmolar contrast.
Severe reactions occurred in 0.22% (ionic) vs 0.04% (non-ionic) of patients.
Non-ionic low-osmolar contrast reduced all categories of adverse reactions by approximately 3-5 fold.

Clinical Implication: Non-ionic low-osmolar contrast should be used exclusively — the dramatic reduction in reaction rates has made high-osmolar agents obsolete.

Limitation: This landmark study established the superiority of non-ionic agents; subsequent improvements in agents have further reduced rates.

Source: Katayama H et al. Radiology 1990;175(3):621-8

Repeat Contrast Reactions and Premedication

Retrospective Study

Mervak BM, Davenport MS, Ellis JH, Cohan RH • Radiology (2015)

Key Findings:

Prior contrast reaction increased the risk of subsequent reaction by 5-6 fold.
Steroid premedication reduced the incidence of subsequent reactions by approximately 50%.
Breakthrough reactions still occurred in 10-15% of premedicated patients with prior reactions.

Clinical Implication: Premedication is valuable but NOT a guarantee of safety. High-risk patients should have alternative imaging considered and emergency equipment available.

Limitation: Premedication compliance was variable; the full protocol (13h, 7h, 1h steroids) was not always completed.

Source: Mervak BM et al. Radiology 2015;277(3):713-22

Non-ionic contrast and premedication reduce but do not eliminate reaction risk.

Australian Context

In Australia, contrast agent administration is governed by RANZCR guidelines and institutional protocols. Non-ionic low-osmolar iodinated contrast agents are the standard for all CT and fluoroscopic contrast studies in Australian practice. The TGA has issued guidance on gadolinium safety, recommending macrocyclic agents (Group I) as the preferred GBCAs, particularly in patients with renal impairment.

Premedication protocols in Australia typically follow the RANZCR recommendations, using a three-dose oral corticosteroid regimen (prednisolone 50mg at 13h, 7h, and 1h before contrast) with an antihistamine. Australian emergency departments and radiology departments are required to have anaphylaxis management protocols and resuscitation equipment (including adrenaline) available wherever contrast media is administered.

The Pharmaceutical Benefits Scheme covers treatment for patients requiring management of contrast reactions, and Australian hospitals maintain contrast reaction guidelines consistent with RANZCR and ANZCOR (Australian and New Zealand Committee on Resuscitation) protocols.

Exam Viva Scenarios

Practice these scenarios to excel in your viva examination

VIVA SCENARIOStandard

EXAMINER

"A patient collapses with severe bronchospasm, hypotension, and urticaria immediately after receiving iodinated contrast for a CT scan."

EXCEPTIONAL ANSWER

This is severe anaphylaxis from iodinated contrast and requires immediate, systematic management: First, STOP the contrast infusion and call for help. My priority sequence is: (1) Adrenaline: 0.5mg (0.5mL of 1:1000) intramuscular injection into the anterolateral thigh — this is the FIRST and MOST IMPORTANT intervention. Adrenaline reverses bronchospasm via beta-2 agonism, supports blood pressure via alpha-1 vasoconstriction, and reduces oedema and mast cell degranulation. I would repeat every 5 minutes if no improvement. (2) Airway and Breathing: Position the patient supine with legs elevated (if hypotensive). Administer high-flow oxygen via non-rebreather mask (15L/min). For bronchospasm: salbutamol nebuliser (5mg). If stridor suggests laryngeal oedema: nebulised adrenaline (5mg of 1:1000 diluted in 5mL saline). Prepare for intubation if airway compromise is not responding. (3) Circulation: Establish large-bore IV access (two large-bore cannulae). Rapid IV fluid resuscitation with normal saline (500mL-1L bolus, repeat as needed for hypotension). Continuous monitoring: ECG, SpO2, blood pressure every 2 minutes. (4) Second-line medications: Promethazine 25mg IV or chlorpheniramine 10mg IV (antihistamine). Hydrocortisone 200mg IV (prevents biphasic reaction). These are adjuncts — they do NOT replace adrenaline. (5) Observation: Minimum 6-hour observation after severe reaction (biphasic reactions can occur hours later). Transfer to a monitored bed. Document the reaction in detail for future reference. The patient should be given a medical alert and referred for allergy clinic follow-up.

KEY POINTS TO SCORE

Adrenaline 0.5mg IM is FIRST LINE — give immediately, do not delay for other treatments

IM into anterolateral thigh (NOT IV unless in cardiac arrest)

Repeat adrenaline every 5 minutes if no improvement

IV fluids and oxygen are second priority

Antihistamines and steroids are adjuncts — never delay adrenaline to give these

COMMON TRAPS

✗Treating with antihistamines instead of adrenaline (antihistamines do NOT treat cardiovascular collapse)

✗Giving adrenaline IV instead of IM (IV adrenaline can cause fatal arrhythmia)

✗Not repeating adrenaline if the first dose is ineffective

✗Inadequate observation period (biphasic reactions occur in up to 20% of anaphylaxis cases)

VIVA SCENARIOStandard

EXAMINER

"A 72-year-old patient with an eGFR of 25 requires a contrast-enhanced CT scan for staging of a suspected bone tumour."

EXCEPTIONAL ANSWER

This patient has severe renal impairment (eGFR 25, Stage 4 CKD) and is at significant risk of contrast-induced nephropathy (CIN). My approach: First, risk assessment: CIN risk is significantly elevated at eGFR less than 30. The risk of temporary renal deterioration may be 10-30% in this population. The risk of requiring dialysis is small but real. I need to balance this against the clinical need — staging a suspected bone tumour is an important indication, and CT may be the best modality for this purpose. Prevention strategy: (1) Confirm the imaging is essential — could MRI without gadolinium provide equivalent staging information? If CT is essential, proceed with maximal renal protection. (2) IV hydration: Normal saline 1mL/kg/hr for 12 hours before and 12 hours after contrast (or at least 6 hours each way if the study is more urgent). This is the single most effective prevention strategy. (3) Use the lowest possible volume of low-osmolar or iso-osmolar non-ionic contrast. (4) Withhold nephrotoxic medications: Stop NSAIDs. Withhold metformin for 48 hours post-contrast (if the patient is on it). Consider withholding ACE inhibitors/ARBs and diuretics if clinically safe. (5) Check serum creatinine at 48-72 hours post-contrast. (6) Ensure the patient is not volume-depleted pre-procedure. Additional considerations: Avoid repeating contrast studies within 72 hours. Discuss the risk-benefit ratio with the patient and the requesting team. If gadolinium MRI is considered as an alternative, use a macrocyclic agent only and check eGFR — although at eGFR 25, gadolinium carries NSF risk with linear agents.

KEY POINTS TO SCORE

eGFR less than 30 = high CIN risk — requires maximal renal protection

IV saline hydration is the most effective prevention (1mL/kg/hr pre and post)

Use lowest possible volume of low-osmolar non-ionic contrast

Withhold nephrotoxins: NSAIDs, metformin (48h post), aminoglycosides

Check creatinine at 48-72 hours to detect CIN

COMMON TRAPS

✗Not considering alternative non-contrast imaging options first

✗Not providing adequate IV hydration (the single most important preventive measure)

✗Forgetting to withhold metformin

✗Not monitoring renal function post-contrast

VIVA SCENARIOChallenging

EXAMINER

"An examiner asks you about nephrogenic systemic fibrosis (NSF) — what it is, who is at risk, and how to minimise the risk."

EXCEPTIONAL ANSWER

Nephrogenic systemic fibrosis (NSF) is a rare but potentially fatal fibrosing condition caused by gadolinium-based contrast agents (GBCAs) in patients with severe renal impairment. Pathophysiology: In patients with normal renal function, GBCAs are rapidly excreted by glomerular filtration (half-life approximately 1.5 hours). In severe renal impairment (eGFR less than 30) or dialysis, the agent remains in the body for much longer, allowing gadolinium to dissociate from its chelate molecule (the 'cage' that makes it safe). Free gadolinium is a toxic heavy metal that deposits in tissues and triggers a fibroblast-mediated fibrotic reaction. NSF manifests as progressive skin thickening and hardening, joint contractures limiting mobility, and in severe cases, fibrosis of internal organs (lungs, liver, heart, diaphragm) which can be fatal. There is no effective treatment once established. Risk factors: (1) eGFR less than 30 (CKD stage 4-5) — the overwhelming risk factor. (2) Dialysis patients. (3) Acute kidney injury (regardless of baseline eGFR). (4) Hepatorenal syndrome. (5) The type of GBCA — linear agents (Group III: gadodiamide, gadoversetamide) have the highest risk because their less stable chelate releases more free gadolinium. Macrocyclic agents (Group I: gadobutrol, gadoterate, gadoteridol) have the most stable chelates and the lowest (possibly zero) NSF risk. Prevention: (1) Check eGFR before ALL gadolinium-enhanced MRI studies. (2) In patients with eGFR less than 30: avoid gadolinium if possible. If essential, use a macrocyclic (Group I) agent at the lowest effective dose. (3) In dialysis patients: if gadolinium is essential, arrange dialysis within 2-3 hours after the contrast study to remove the agent. (4) Document the assessment and clinical justification for gadolinium use in renal impairment.

KEY POINTS TO SCORE

NSF is caused by free gadolinium released from contrast agents in severe renal impairment (eGFR less than 30)

Presents with progressive skin thickening, joint contractures, and potentially fatal organ fibrosis

No effective treatment — prevention is critical

Linear agents (Group III) have the highest NSF risk; macrocyclic (Group I) have the lowest

Check eGFR before ALL gadolinium MRI; use macrocyclic agents if gadolinium is essential in renal impairment

COMMON TRAPS

✗Not knowing what NSF is (the name alone is a clue: nephrogenic = kidney-related)

✗Not knowing the difference between linear and macrocyclic GBCAs

✗Not checking eGFR before gadolinium administration

✗Assuming gadolinium is safe because it is 'not iodinated'